• Breast Cancer Partnership Raises Over Half a Million Dollars for Research into Inflammatory Breast Cancer and More


    Susan G. Komen®, the Milburn Foundation and the Inflammatory Breast Cancer Research Foundation today announced that they have raised nearly $550,000 to fund research into inflammatory breast cancer (IBC) as well as other critical breast cancer research and community health programs. IBC is a less common but very aggressive form of breast cancer.

    Throughout the month of March, Milburn and the Inflammatory Breast Cancer Research Foundation teamed up to match all donations made to Komen up to a predetermined goal – a campaign which ultimately raised more than half a million dollars, and exceeded the goal ten-fold. In total, over $548,000 was raised through the campaign, which will support, in part, research aimed at finding new ways of detecting and treating IBC.

    This marks the second time the three organizations have partnered to advance IBC research. Last fall, the partners announced two funding opportunities for investigators with novel ideas about diagnosis and treatment of IBC. Recipients of these awards include:

    • John Martens, Ph.D., from Erasmus Universitair Medisch Centrum Rotterdam, who received funding to combine patient information from an established Dutch IBC registry with the latest genomic technology to improve the diagnosis, monitoring, and treatment of IBC.
    • Mihaela Skobe, Ph.D. from the Icahn School of Medicine at Mount Sinai, also received funding to understand how the interactions between Triple Negative IBC and the lymphatic system influence the aggressiveness of the disease, ultimately providing insight on potential new treatment strategies.

    “Our partnership has already allowed us to fund important research, and will go a long way toward helping to reduce deaths from breast cancer,” said Ellen Willmott, interim President and CEO for Susan G. Komen. “Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026, but we know we will not be able to achieve this alone – only as a community, which is why our partnership with the Milburn Foundation and the Inflammatory Breast Cancer Research Foundation is so valuable.”

    “The success of this partnership proves that strategic collective action across multiple charities can yield powerful results for specialized research” said Bryon Davis, President of the Milburn Foundation. "This partnership was actively designed and facilitated for results, requiring all parties to look at challenges in new ways and leveraging each organization's strengths."

    “Research progress, in a disease like IBC, requires vision, creative thinking and action. Through the collaborative IBC research grants and the recent matching gift campaign we’re developing a new model for meeting the needs of those facing an IBC diagnosis,” said Ginny Mason, RN, BSN, Executive Director of the IBC Research Foundation.

    A portion of the funds from the March campaign will be used to provide additional research support to the most promising of the two recipients named above, following a review of their progress to date and other prerequisites. To date, Komen has invested $9.1 million into research focused on IBC – part of the organization’s $920 million research investment since its founding in 1982.